| Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for … JP van Meerbeeck, R Gaafar, C Manegold, RJ Van Klaveren, ... Journal of Clinical Oncology 23 (28), 6881-6889, 2005 | 718 | 2005 |
| Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non–small-cell lung cancer: A phase III trial of the European … EF Smit, JPAM van Meerbeeck, P Lianes, C Debruyne, C Legrand, ... Journal of Clinical Oncology 21 (21), 3909-3917, 2003 | 428 | 2003 |
| Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial PE Van Schil, P Baas, R Gaafar, AP Maat, M Van de Pol, B Hasan, ... European Respiratory Journal 36 (6), 1362-1369, 2010 | 267 | 2010 |
| Breast cancer in Egypt: a review of disease presentation and detection strategies S Omar, H Khaled, R Gaafar, AR Zekry, S Eissa, O El Khatib EMHJ-Eastern Mediterranean Health Journal, 9 (3), 448-463, 2003, 2003 | 238 | 2003 |
| Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo … LM Krug, HL Kindler, H Calvert, C Manegold, AS Tsao, D Fennell, ... The Lancet Oncology 16 (4), 447-456, 2015 | 211 | 2015 |
| Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic … F Efficace, A Bottomley, EF Smit, P Lianes, C Legrand, C Debruyne, ... Annals of oncology 17 (11), 1698-1704, 2006 | 210 | 2006 |
| Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell … T Cufer, E Vrdoljak, R Gaafar, I Erensoy, K Pemberton, SIGN Study Group Anti-cancer drugs 17 (4), 401-409, 2006 | 202 | 2006 |
| Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised … GV Scagliotti, R Gaafar, AK Nowak, T Nakano, J van Meerbeeck, S Popat, ... The Lancet Respiratory Medicine 7 (7), 569-580, 2019 | 140 | 2019 |
| A mini review on cancer of unknown primary site: a clinical puzzle for the oncologists N Pavlidis, H Khaled, R Gaafar Journal of advanced research 6 (3), 375-382, 2015 | 138 | 2015 |
| A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based … RM Gaafar, VF Surmont, GV Scagliotti, RJ Van Klaveren, D Papamichael, ... European Journal of Cancer 47 (15), 2331-2340, 2011 | 117 | 2011 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 107 | 2019 |
| Patient‐mediated factors predicting early‐and late‐stage presentation of breast cancer in Egypt JM Stapleton, PB Mullan, S Dey, A Hablas, R Gaafar, IA Seifeldin, ... Psycho‐Oncology 20 (5), 532-537, 2011 | 100 | 2011 |
| European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and … A Ardizzoni, C Manegold, C Debruyne, R Gaafar, E Buchholz, EF Smit, ... Clinical cancer research 9 (1), 143-150, 2003 | 96 | 2003 |
| Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III … A Bottomley, C Coens, F Efficace, R Gaafar, C Manegold, S Burgers, ... Journal of Clinical Oncology 25 (36), 5770-5776, 2007 | 92 | 2007 |
| European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without … JP Van Meerbeeck, R Gaafar, C Manegold, RJ Van Klaveren, ... J Clin Oncol 23 (28), 6881-6889, 2005 | 74 | 2005 |
| NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial V Gregorc, RM Gaafar, A Favaretto, F Grossi, J Jassem, A Polychronis, ... The Lancet Oncology 19 (6), 799-811, 2018 | 71 | 2018 |
| Epidemic of mesothelioma in Egypt RM Gaafar, NHA Eldin Lung Cancer 49, S17-S20, 2005 | 59 | 2005 |
| Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for … MER O’Brien, RM Gaafar, S Popat, F Grossi, A Price, DC Talbot, T Cufer, ... European journal of cancer 49 (13), 2815-2822, 2013 | 56 | 2013 |
| Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a … D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 32 (10), 1245-1255, 2021 | 45 | 2021 |
| A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials J Francart, E Vaes, S Henrard, C Legrand, P Baas, R Gaafar, ... European journal of cancer 45 (13), 2304-2311, 2009 | 45 | 2009 |
